Recent

% | $
Quotes you view appear here for quick access.

Assured Guaranty Ltd. Message Board

vskomarovsky 9 posts  |  Last Activity: Jul 20, 2015 9:41 PM Member since: Feb 9, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Rules of the squeeze game?

    by bf109gee Jul 20, 2015 11:57 AM
    vskomarovsky vskomarovsky Jul 20, 2015 9:41 PM Flag

    Excellent assumption!

  • Reply to

    interesting trial analysis from twitter

    by immediatereliefxxx Jul 16, 2015 4:05 PM
    vskomarovsky vskomarovsky Jul 17, 2015 1:39 PM Flag

    Different set of investors and SRPT is a bigger threat for all hedge funds that got accustomed to play it up and down.

  • Reply to

    interesting trial analysis from twitter

    by immediatereliefxxx Jul 16, 2015 4:05 PM
    vskomarovsky vskomarovsky Jul 17, 2015 11:30 AM Flag

    Tenfold would give us just $50. We lived with a pain worth of $500

  • Reply to

    Margaret Hamburg

    by richs375 Jul 16, 2015 5:47 PM
    vskomarovsky vskomarovsky Jul 16, 2015 7:17 PM Flag

    Peter Fitzhugh Brown - Margie's husband. He is CEO of Renaissance Technologies hedge fund, which trades in markets around the world, and has employed complex mathematical models to analyze and execute trades, many of them automated. Renaissance uses computer-based models to predict price changes in easily traded financial instruments. These models are based on analyzing as much data as can be gathered, then looking for non-random movements to make predictions.[ Some also attribute Renaissance performance to employing financial signal processing techniques such as pattern recognition.
    Presumably, SRPT was shorted by Brown with the tips from Margie. Crime yet to be punished.

  • Reply to

    Sarepta Trials

    by usagary1 Jul 16, 2015 3:20 PM
    vskomarovsky vskomarovsky Jul 16, 2015 3:34 PM Flag

    Can you see your hair grow?

  • Reply to

    Sarepta Trials

    by usagary1 Jul 16, 2015 3:20 PM
    vskomarovsky vskomarovsky Jul 16, 2015 3:26 PM Flag

    "to Treat Advanced Stage Duchenne Muscular Dystrophy Condition." ADVANCED! Isn't it new?

    Sentiment: Strong Buy

  • Reply to

    Translarna?

    by vskomarovsky Mar 28, 2015 3:43 PM
    vskomarovsky vskomarovsky Mar 29, 2015 1:42 AM Flag

    KGB is renamed into FSB. Your parallel is better.

  • Reply to

    Translarna?

    by vskomarovsky Mar 28, 2015 3:43 PM
    vskomarovsky vskomarovsky Mar 28, 2015 8:14 PM Flag

    FDA = Kremlin

  • vskomarovsky by vskomarovsky Mar 28, 2015 3:43 PM Flag

    The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to naproxcinod, an investigational treatment being developed by Nicox S.A. for patients with Duchenne muscular dystrophy (DMD). The designation is given to drugs or biological products that address rare conditions and is meant to offer drug developers a series of benefits to accelerate regulatory processing.

    Being granted orphan drug designation means that Nicox may now qualify for development incentives, such as seven years of marketing exclusivity in the United States after being approved by the FDA for the indication, as well as possible tax credits and reduced fees, as announced by the company in a press release.

    Naproxcinod is a Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) anti-inflammatory investigation drug that already demonstrated its promising capacities during preclinical studies conducted in models of muscular dystrophy. The drug was also granted European orphan drug designation to treat DMD by the European Medicines Agency (EMA) in October 2013.

    The potential therapy is being investigated by Nicox, with support from an undisclosed financial partner, in patients who suffer from DMD. The undisclosed financial partner has been given the exclusive right to invest in naproxcinod, as well as the option to invest in next generation nitric oxide (NO)-donors, if the results of the evaluation are satisfactory to the partner at the end of the evaluation period.

    Despite being a rare disease, Duchenne is the most common but also severe form of muscular dystrophy. Being an inherited condition, it provokes the weakness and loss of muscle. Therefore, the FDA and the EMA are committed to supporting the development of potential treatments for the disease, as well as numerous others in the same situation, by granting the status and its benefits.

    The biopharmaceutical company PTC Therapeutics, Inc., has also been granted the orphan drug designation for its novel product Translarna (ataluren) as a treatment for Mucopolysaccharidosis I (MPS I), by both the FDA and the EMA, making it the third indication for Translarna that has received an orphan drug designation, with the previous two being DMD and cystic fibrosis.

AGO
25.40+0.55(+2.21%)Jul 29 4:00 PMEDT